Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23351729 | 0.84 | KDM1A (0.48) | KDM1AKDM1BALDH1A1TDP1MAPT | |
| SCHEMBL23557091 | 0.82 | ALDH1A1 (0.39) | KDM1AKDM1BALDH1A1TDP1MAPT | |
| SCHEMBL29362089 | 0.78 | KDM1A (0.44) | KDM1AKDM1BALDH1A1TDP1MAPT | |
| SCHEMBL811929 | 0.78 | KDM1A (0.44) | KDM1AKDM1BALDH1A1TDP1MAPT | |
| SCHEMBL7940907 | 0.78 | AHR (0.44) | KDM1AKDM1BALDH1A1TDP1MAPT | |
| SCHEMBL14396118 | 0.76 | HSD17B10 (0.36) | KDM1AKDM1BALDH1A1TDP1MAPT | |
| SCHEMBL23716731 | 0.74 | HTR2A (0.37) | KDM1AMAPTHTT | |
| SCHEMBL13330784 | 0.74 | GAA (0.43) | KDM1AKDM1BALDH1A1TDP1 | |
| SCHEMBL7534006 | 0.74 | ALDH1A1 (0.46) | KDM1AKDM1BALDH1A1TDP1MAPT | |
| SCHEMBL23655699 | 0.70 | RAPGEF4 (0.36) | KDM1AKDM1BALDH1A1TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | KDM1A 2773/4885KDM1B 1972/4885ALDH1A1 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.